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Abstract
The molecular epidemiology of 33 Escherichia coli and 81 Klebsiel-
la pneumoniae extended-spectrum b-lactamase-producing health-
care-associated and community-acquired isolates collected in the
Helsinki district during 2000–2004 was investigated. Clonality
studies, antimicrobial susceptibility and genotyping of the isolates
were performed. Newly emerging CTX-M-producing E. coli and
blaSHV-12-producing K. pneumoniae isolates were detected. Clonal
clusters of both species persisted throughout the study period.
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The proportion of extended-spectrum b-lactamase (ESBL)-
producing Escherichia coli and Klebsiella pneumoniae has been
increasing worldwide in both community-acquired and health-
care-associated infections [1–4]. Increasing frequencies of
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ESBL-positive E. coli and K. pneumoniae were observed in the
city of Helsinki during the 2000s. We conducted this study to
identify longitudinal trends in the emergence of ESBL-produc-
ing E. coli and K. pneumoniae strains, and to characterize their
molecular epidemiology. (These results were presented in
part at the 6th International Conference of the Hospital
Infection Society, Amsterdam, October 2006.)
The city of Helsinki is a large, well-deﬁned geographical
area with a public healthcare system providing virtually all
healthcare to its more than a million inhabitants. The health-
care system consists of a tertiary-care hospital, seven city hos-
pitals and 30 primary-care ofﬁces. The study population
consisted of all patients treated by the Helsinki city healthcare
system from whom an E. coli or K. pneumoniae isolate, with a
0.0
1.0
2.0
3.0
4.0
5.0
6.0
2000 2001 2002 2003 2004
Year
%
 
ES
BL
-p
ro
du
ci
ng
 is
ol
at
es
 K. pneumoniae 
E. coli pus & blood
E. coli urine 
FIG. 1. Yearly extended-spectrum b-lactamase (ESBL)-producing iso-
lates, as percentages of the total species and clinical specimen combi-
nations indicated, in Helsinki city (January 2000 to December 2004).
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FIG. 2. Dendrograms of (a) Escherichia coli (n = 33) and (b) Klebsiella
pneumoniae (n = 81) XbaI pulsed-ﬁeld gel electrophoresis (PFGE)
proﬁles, generated using Bionumerics software, the Dice coefﬁcient,
and the UPGMA (unweighted pair group method with arithmetic
mean) algorithm. The dotted line deﬁnes a similarity of 85%. For
E. coli, band tolerance was set at 3.0%, and optimization at 2%; for
K. pneumoniae, band tolerance was set at 3.2%, and optimization at
2%. The b-lactamase genes are marked by coloured dots: blaCTX-M-1
(green); blaCTX-M-9 (violet); undeﬁned blaCTX-M (dark green); blaSHV-12
(black); blaSHV-11 (grey); blaSHV-5 (blue); blaSHV-2/2A (light blue);
blaSHV-1 (yellow); and blaTEM (pink). The dot for the E. coli strain
with both a blaCTX-M-1 and a blaCTX-M-9 gene is half green and half
violet. The star in the K. pneumoniae dendrogram indicates the
index case. The resistance phenotype (all isolates of that PFGE type
were resistant to the mentioned antimicrobial agents) is indicated
next to the PFGE type: I, AMP–CTX/CAZ–CEF–TET; II, AMP–
CTX–CEF–CXM–NAL–CIP–TOB; and III, AMP–CAZ–CTX–NAL–
NIT–CIP. AMP, ampicillin; CIP, ciproﬂoxacin; CEF, cephalothin;
NAL, nalidixic acid; NIT, nitrofurantoin; CTX, cefotaxime; CAZ,
ceftazidime; CXM, cefuroxime; TOB, tobramycin; TET, tetracycline.
CMI Research Notes 1159
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1155–1171
resistance phenotype implying the presence of an ESBL, was
isolated between 2000 and 2004. Altogether, 746 patients (of
whom 48 were bacteraemic) with ESBL-producing E. coli and
91 with ESBL-producing K. pneumoniae colonization or infec-
tion, were included. Only one isolate per patient was studied.
An isolate was deﬁned as healthcare-associated if it was
obtained >48 h after hospital admission, or the patient had
been hospitalized within a year prior to culture (excluding
clinic visits), or if the patient was a resident in a long-term-
care facility; all other isolates were deﬁned as community-
acquired. The study protocol was approved by the ethics
committee of the Helsinki city hospitals.
The increase in ESBL-producing E. coli (p <0.001) mirrored
the increase in annual incidence rates of ESBL cases: from
0.5/100 000 population in 2000 to 69.0/100 000 in 2004. The
mean age of patients with E. coli was 77.2 years (median
78.1 years), and the mean age of those with K. pneumoniae
was 69.9 years (median 71.8 years). The majority (77%) of
cases occurred among the elderly (>65 years), with only 13
of patients being children. Of the non-bacteraemic E. coli iso-
lates, 90% were isolated from urine, 8% from wounds, and
2% from pus.
MICs were determined according to CLSI guidelines [5,6].
All isolates were screened by PCR for ESBL genes, and
pulsed-ﬁeld gel electrophoresis (PFGE) analysis was per-
formed, as previously described [7–9]. The isolates were
considered to belong to the same PFGE type if the coefﬁ-
cient of similarity was ‡85%. The number of ESBL-producing
E. coli isolates, from urine, blood and pus specimens,
increased signiﬁcantly (p <0.001, chi-square test for trend)
during the whole study period. Starting at below 1% in 2000,
at the end of the year 2004, 5% of blood and pus isolates
and 2.5% of urine isolates were ESBL-producing (Fig. 1). The
number of K. pneumoniae isolates with an ESBL phenotype
also increased signiﬁcantly (p <0.001, chi-square test for
trend) at the beginning of the study period, but no increase
was detected during the years 2003 and 2004 (Fig. 1).
Altogether, 33 of the 48 bacteraemic E. coli isolates were
available for analysis. Three isolates autodigested and there-
fore could not be analysed by PFGE, and the rest of the iso-
lates could not be recultured. Thirty-two of the isolates
were healthcare-associated, and one was community-
acquired. Among them, PFGE type AE, consisting of 13 (40%)
isolates, was dominant (Fig. 2). A less important PFGE type,
BE, consisting of eight isolates (25%), was also identiﬁed.
In total, 81 of the 91 K. pneumoniae isolates were available
for PCR and PFGE analysis. Three isolates autodigested and
could therefore not be analysed, and seven isolates could
not be recultured. Forty-three had originated from urine
samples, 36 from pus and wounds, and two from blood cul-
tures. One major PFGE type, AK, consisting of 60 (74%) iso-
lates, was identiﬁed (Fig. 2). The isolates of this type were
collected from 16 different wards; 59 were healthcare-associ-
ated, and only one was community-acquired. The combina-
tion of blaSHV-12 and blaTEM was the most prevalent gene
combination (75%) in this PFGE type.
The majority of the ESBL-producing E. coli and K. pneumo-
niae isolates included in this study were multidrug-resistant
(MDR), i.e. resistant to more than three different antimicro-
bial drug classes. In particular, the prevalence of ciproﬂoxacin
resistance was high (82%). All of the E. coli isolates of PFGE
type AE and seven (88%) of PFGE type BE were MDR
(Fig. 2). Similarly, 56 (93%) of type AK K. pneumoniae isolates
were MDR (Fig. 2). Only one carbapenem-resistant K. pneu-
moniae isolate was detected. Although the frequency of carb-
apenem-resistant isolates has increased worldwide, owing to
the emergence of KPC carbapenemases and metallo-b-lacta-
mases, carbapenem-resistant K. pneumoniae strains have
remained rare in Finland.
In Finland, the number of ESBL-producing E. coli and
K. pneumoniae isolates had been very low until the end of
the 1990s [10], but our results indicate that the situation has
changed. We have shown that the number of new infections
caused by ESBL-producing E. coli strains increased dramati-
cally (Fig. 1) within 4 years (2000–2004) in the Helsinki city
area. On the basis of data from 2005 onwards, this trend
seems to be continuing (unpublished results). Of course, a
similar change in the incidence of ESBL-producing E. coli to
that observed in this study has been observed in several
other countries during the same time period [11–13]. As
in other countries, in the Helsinki region, the CTX-M-1-type
b-lactamases are predominant among ESBL-positive E. coli
isolates, regardless of clonal background. On the other hand,
the increase in the frequency of ESBL-producing K. pneumo-
niae isolates was mainly due to the emergence of one
K. pneumoniae clone producing SHV-12.
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Abstract
Nontuberculous mycobacteria (NTM) are being increasingly iso-
lated in clinical laboratories and present technical and therapeu-
tic challenges. In the present study, we report our experience
with the identiﬁcation of NTM received from 12 Lisbon hospitals
over a 3-year period using GenoType Mycobacterium (CM/AS)
assays (HAIN Lifescience GmbH, Nehren, Germany). Together,
the two kits identiﬁed 96.6% of all NTM isolates tested. Among
the 18 NTM species identiﬁed, Mycobacterium avium complex
was the most frequent, although it accounted for only 34% of all
NTM. Introducing these methods for the rapid identiﬁcation of
NTM highlights the importance of NTM as potential pathogens
and assisted the selection of adequate therapy.
Keywords: Atypical, identiﬁcation, molecular, mycobacteria,
nontuberculous
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Although Mycobacterium tuberculosis is the main cause of
mycobacteriosis in humans, other species of mycobacteria
may also cause infection [1,2]. The increasing importance of
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